title: Different gamma/delta T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation.
abstract: TCR gamma/delta profiles were analyzed in 13 multiple myeloma patients after allogeneic non-myeloablative transplantation. Results show that both aGVHD and minimal residual disease (MRD) eradication did significantly affect TCR gamma/delta profile. During follow-up, six patients developed an aGVHD episode; in five of them, this event fitted with a modification of the TCR profile. Eleven patients achieved PCR-negativity during follow-up. In the 90% of them, the appearance of a new predominant TCR peak was concomitant to the disappearance of the IgH clone. These results suggest that different T gamma/delta populations would sustain GVM and GVH effects after non-myeloablative allogeneic transplant.
authors.affiliation: Department of Oncology, Transplant and Advances in Medicine, Section of Hematology, University of Pisa, Ospedale S. Chiara, Via Roma, 56, 56100 PISA, Italy. s.galimberti@med.unipi.it
authors.forename: Sara
authors.initials: S
authors.lastname: Galimberti
authors.forename: Edoardo
authors.initials: E
authors.lastname: Benedetti
authors.forename: Fortunato
authors.initials: F
authors.lastname: Morabito
authors.forename: Iacopo
authors.initials: I
authors.lastname: Petrini
authors.forename: Barbara
authors.initials: B
authors.lastname: Battolla
authors.forename: Federico
authors.initials: F
authors.lastname: Papineschi
authors.forename: Rita
authors.initials: R
authors.lastname: Fazzi
authors.forename: Elena
authors.initials: E
authors.lastname: Ciabatti
authors.forename: Massimo
authors.initials: M
authors.lastname: Martino
authors.forename: Mariella
authors.initials: M
authors.lastname: Cuzzola
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Console
authors.forename: Pasquale
authors.initials: P
authors.lastname: Iacopino
authors.forename: Mario
authors.initials: M
authors.lastname: Petrini
mesh_terms: D000328:Adult; D000368:Aged; D002999:Clone Cells; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000235:genetics* / Q000276:immunology / Q000628:therapy; D020350:Graft vs Tumor Effect / Q000235:genetics* / Q000276:immunology; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000235:genetics* / Q000276:immunology / Q000628:therapy*; D018365:Neoplasm, Residual / Q000235:genetics* / Q000276:immunology / Q000628:therapy; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000032:analysis / Q000235:genetics*; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D007143:Immunoglobulin Heavy Chains; D016692:Receptors, Antigen, T-Cell, gamma-delta